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Metabolomics refers to the analysis and the study of the 
metabolome which encompasses the totality of the metabolites 
of a biological system, that is, the intermediate and end‑point 
products of metabolism (1). Together with other omics 
technologies, including genomics and pharmacogenomics, 
metabolomics is currently recognized as the core of personalized 
medicine, which aims to predict the individual susceptibility to a 
disease or outcome before a therapeutic intervention (2–4). 
The practical value of metabolomics, which is used as a tool 
to investigate metabolic phenotypes linked to genetics and 
environmental effects, has already been demonstrated for a 
number of diseases including metabolic syndrome, diabetes, 
and infections (5–7). While early metabolomics studies focused 
on the discovery of single molecules as specific biomarkers, it is 
now widely accepted that pathological processes rely on much 
more complex metabolic changes, which places metabolomics 
at the core of dissecting pathological phenotypes (8). 
As well as the large number of metabolites that can be 
present in biological fluids, their physico‑chemical diversity and 
wide range of concentrations (often several orders of magnitude) 
represents a major analytical challenge and no single analytical 
platform is currently able to provide a complete coverage of 
the metabolome. Nuclear magnetic resonance (NMR) and 
mass spectrometry (MS) based techniques, including liquid 
chromatography (LC), gas chromatography (GC), and capillary 
electrophoresis (CE) are commonly used in metabolomics, often 
in combination. LC coupled to MS, especially in reversed‑phase 
chromatographic mode, remains the gold standard 
technique for untargeted metabolomics. Reversed‑phase 
LC is characterized by high sensitivity, separation efficiency, 
and throughput, particularly when used in combination 
with sub‑2‑µm particle size columns (ultrahigh‑pressure LC 
[UHPLC]) or superficially porous particles (core–shell or 
fused‑core technology). Reversed‑phase LC is suitable for the 
analysis of a large fraction of biological compounds but highly 
polar molecules such as saccharides, phosphates, amino 
acids, nucleic acids, and short‑chain organic acids are poorly 
retained on typical reversed phase stationary phases (9,10). 
This is a clear limitation because they represent a large fraction 
of important endogenous metabolites (11). The poor retention 
behaviour of polar metabolites under most reversed phase 
conditions also leads to co‑elution with matrix interferences, 
resulting in significant matrix effects during electrospray 
ionization (ESI), and leading to poor sensitivity and inaccurate 
data (12). Several attempts have been proposed to increase 
the retention of polar compounds in reversed‑phase LC, for 
example, by using polar‑embedded or polar‑endcapped groups 
in combination with C18 phases; adding ion‑pairing agents to 
the mobile phase for charged compounds; or derivatizing the 
polar functional group into a more hydrophobic one (13,14). 
However, all of these strategies suffer from limitations in terms 
of instrument fouling, sensitivity, or partial metabolite coverage. 
Hydrophilic interaction chromatography (HILIC) is therefore 
considered as an effective approach to analyze the polar 
fraction of the metabolome.
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Hydrophilic interaction chromatography (HILIC) was introduced more than two decades ago and has 
garnered much attention. Characterized by a hydrophilic stationary phase used in combination with 
an aqueous organic mobile phase, numerous improvements have been achieved and HILIC is now 
considered as an attractive alternative to reversed-phase phase liquid chromatography (LC) for many 
applications. HILIC provides several advantages over reversed-phase LC for the analysis of polar 
compounds, including higher retention of polar metabolites, enhanced mass spectrometric sensitivity, 
moderate back-pressure — even at high flow rates, or when used with sub-2-µm particle size — and 
orthogonal selectivity. Several important technical developments have been proposed during the last 
decade that foster its use in metabolomics. This review presents an overview of the most recent technical 
improvements and applications of HILIC analysis in untargeted clinical metabolomics and discusses 
important practical considerations, including the selection of the optimal column chemistry, appropriate 
eluents, sample preparation, and data analysis. 
KEY POINTS
•	 HILIC has become an attractive alternative to 
reversed‑phase LC.
•	 The use of HILIC and its benefits in clinical metabolomics 
is discussed.
•	 Practical guidelines for the successful implementation of 
HILIC analysis are presented.
•	 An overview of commercially available columns is given.
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In HILIC, a term first coined by Alpert in 1990 (15), a polar 
stationary phase is used with a relatively hydrophobic mobile 
phase composed of an aqueous—organic mixture usually 
containing approximately 5% to 40% of water, forming a 
water‑enriched layer of partially immobilized eluent on the 
stationary phase. The stationary phase generally consists 
of underivatized bare silica or silica modified by functional 
groups such as amides, diols, amines, or zwitterionic moieties. 
The mobile phase is composed of water‑miscible aprotic 
polar organic solvents, such as acetonitrile, used with volatile 
buffers (16). The retention mechanisms occurring in HILIC are 
rather complex and not yet completely understood but involve 
hydrophilic partitioning, dipole–dipole interaction, hydrogen 
bond, and electrostatic interaction (11,13,16–19). HILIC shows 
several advantages compared to reversed‑phase LC, such as 
an increased analyte diffusivity in the organic‑rich mobile phase 
(lower C‑term contribution to the Van Deemter curve) (20); lower 
backpressure because of low viscosity of the mobile phase 
(21); enhanced MS signal as a result of better eluent desolvation 
(increased ionization efficiency) (22,23); and the possibility of 
direct injection of organic extracts as usually obtained by protein 
precipitation or extraction (16,24).
Even though multiple studies over the last decade have 
demonstrated the usefulness of HILIC, it remains rarely used 
compared with reversed‑phase LC in untargeted metabolomics. 
This reluctance may be because HILIC is less flexible and not 
as straightforward as reversed‑phase LC. Indeed, because of 
the complexity of the retention mechanisms, certain practical 
aspects should be considered to ensure high quality data. 
The following sections provide a practical guide for the 
implementation of HILIC in untargeted clinical metabolomics. 
Sample Preparation
When using HILIC, an optimal sample preparation is not 
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Figure 1: Chromatographic separations of a representative set of metabolites belonging to different classes — amino acids, 
nucleosides, organic acids, and carbohydrates — using various HILIC conditions. (a): Luna HILIC (cross‑linked diol groups) 
column, 20 mM ammonium formate at pH 3.5; (b): Luna HILIC (cross‑linked diol groups) column 20 mM ammonium acetate at 
pH 6.0; (c): ZIC‑HILIC (sulphobetaine) column, 20 mM ammonium formate at pH 3.5; (d): ZIC‑HILIC (sulphobetaine) column, 
20 mM ammonium acetate at pH 6.0; (e): Luna NH2 column, 20 mM ammonium acetate at pH 9.0. Analytes: (1) aspartic acid, 
(2) proline, (3) threonine, (4) tyrosine, (5) guanosine, (6) inosine, (7) adenine, (8) malic acid, (9) hippuric acid, (10) nicotinic 
acid, (11) rhamnose, (12) trehalose, and (13) maltose. HILIC–MS experiments were performed on an UltiMate 3000 RSLC LC 
system (Thermo/Dionex) hyphenated to a MaXis Impact HD UHR‑QqTOF (Bruker) operating in the negative ESI mode. All 
columns were 100 mm × 2.0 mm, 3‑µm (3.5‑µm for ZIC‑HILIC); mobile phase: buffer (A) and acetonitrile (B); flow rate was 
300 µL/min with the following gradient: 95% B for 1 min, 95–5% B for 10 min, 5% B for 3 min. Standards were dissolved in pure 
acetonitrile and 2 µL were injected. 
only critical for ensuring maximal recovery of a large range 
of metabolites but also for chromatographic separation 
performance. Untargeted metabolomics implies the analysis 
of the highest number of metabolites and, hence, a sample 
pre‑treatment as simple as possible. Human and animal 
samples used for clinical metabolic profiling include a wide 
range of biological matrices such as blood‑derived samples, 
urine, saliva, tears, cerebrospinal fluid, tissues, and faeces 
(25). Among them, blood plasma and urine represent by far the 
majority of applications and their pre‑treatment is discussed in 
this article. 
Plasma Samples: Plasma is usually preferred over serum 
because of artifact formation, which may occur during blood 
clotting (26,27). However, plasma has an overall higher protein 
content, underlining the importance of an efficient protein 
removal step. Protein precipitation (PP) by the addition of 
cold organic solvent is the most commonly used preparation 
method because it allows for a simultaneous quenching and 
non‑selective sample pre‑treatment. Moreover, solvent‑based 
PP techniques lead to higher metabolite coverage compared 
to heat or organic acid treatment (28). The composition and 
volume of the organic solvent has a major effect on both 
the metabolic coverage and the protein removal. In general, 
acetonitrile and acetone give better results in terms of protein 
removal efficiency while methanol and ethanol (EtOH), usually 
in a ratio ≥ 2.5:1 (solvent:sample, v/v) result in a higher number 
of metabolites detected and are commonly considered the 
first choice when combined with reversed‑phase LC analysis 
(28,29). In HILIC analysis, the nature of the sample diluent has 
been shown to be much more critical than in reversed‑phase 
LC. It is well known that peak distortion is observed in the 
presence of large amounts of water in the injected sample, 
especially for early‑eluting peaks because of the significant 
difference in elution strength between the highly organic mobile 
phase and the dissolution solvent (30,31). Such effects are also 
observed when using polar protic solvents such as methanol, 
EtOH, and isopropanol (iPA). Solvents with higher hydrogen 
bonding donor capability (water > methanol > EtOH > iPA >> 
acetonitrile) may disturb the water‑enriched layer at the surface 
of the stationary phase leading to deteriorated peak shapes. It 
is therefore recommended to use the lowest amount of protic 
solvents in the sample plug (that is, ≤10–20%, depending on 
the stationary and mobile phase composition) and inject less 
than 1% of the column volume (for example, ~2 µL for 100 mm 
× 2.1 mm i.d. columns). For compounds presenting solubility 
issues in pure acetonitrile, acceptable peak shapes may be 
obtained by using a mixture of acetonitrile /iPA (50:50, v/v), 
provided that the volume injected is reduced to its minimum (31). 
Urine Samples: Urine is usually simply filtrated and diluted 
five‑ to 10‑fold with buffers or water prior to reversed‑phase 
LC–MS analysis (known as dilute-and-shoot). However, in HILIC 
analysis, this straightforward strategy cannot be applied and 
urine samples have to be diluted with acetonitrile, leading to 
precipitation of proteins and salts. Compared to plasma, urine 
presents a relatively low amount of proteins (0.5–1 g/L). Hence, 
in high‑throughput studies, urine samples are commonly diluted 
4–5 times with a mixture of acetonitrile/water 3:1 (v/v). This 
allows for a sufficient dilution of salts and proteins, which, in turn, 
enables the direct injection of samples and results in acceptable 
separation performance. Nevertheless, proteinuria is a common 
clinical abnormality of many diseases; if samples are suspected 
to contain a higher amount of proteins, centrifugation and 
injection of the acetonitrile supernatant is mandatory to avoid 
on‑column precipitation of residual proteins. 
While reversed‑phase LC is prone to mass overload, HILIC 
is prone to volume overload phenomena, which may lead to 
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Figure 2: Sum of scores obtained under different experimental conditions in positive and negative ESI modes. (a): HILIC 
experiments with diol (blue), cyano (red), and amine (green) stationary phases; (b): reversed‑phase LC experiments with 
core–shell C18 (purple), core–shell XB‑C18 (C18 with di‑isobutyl side chains, brown), and core–shell pentafluorophenyl (PFP, 
grey) stationary phases. The scores represent the chromatographic performance and were calculated based on the sensitivity 
(signal‑to‑noise ratio), peak sharpness, peak symmetry, and retention time. See (39) for further details. Experimental conditions: 
(1) acetonitrile/0.1% formic acid, (2) acetonitrile/20 mM ammonium acetate at pH 4, (3) acetonitrile/20 mM ammonium acetate 
pH 9, (4) acetonitrile/20 mM ammonium acetate pH 7, (5) methanol/0.1% formic acid, (6) methanol/20 mM ammonium 
acetate at pH 4, and (7) methanol/20 mM ammonium acetate pH 9. Adapted and reproduced with permission from Journal of 
Chromatography B 927, D.P. Kloos, H. Lingeman, W.M. Niessen, A.M. Deelder, M. Giera, and O.A. Mayboroda, Evaluation of 
different column chemistries for fast urinary metabolic profiling, 90–96 (2013) © Elsevier.
severe peak tailing and distortion, especially if the sample 
diluent composition is not optimal (24,32,33). Whatever the 
biological matrix, the injection volume should remain as low 
as possible, preferentially less than 1% of the total column 
volume (34). If sensitivity becomes an issue, samples may be 
pre‑concentrated to increase the injected amount while keeping 
a minimal injected volume. 
Chromatographic Separation
Compared with reversed‑phase LC, HILIC usually shows lower 
intra‑day and batch‑to‑batch retention time repeatability, longer 
equilibration time, and difficulties in predicting the retention 
behaviour as a result of the multimodal retention mechanism. 
These limitations do not foster the widespread use of HILIC 
in large cohort metabolomics studies. However, their impact 
can be significantly lowered with practical measures, including 
repeatable preparation of mobile phase (accurate salts 
concentration and pH titration) as well as sufficient column 
equilibration.
HILIC stationary phases usually consist of bare silica or 
polymer material modified with polar functional group(s), which 
allows for hydrophilic partitioning of the analytes between 
the water‑enriched layer and the mobile phase, and other 
retention mechanisms. As a result of the complexity of HILIC 
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Figure 3: 2D‑representations obtained for precipitated plasma and diluted urine showing m/z values as a function of retention 
times of endogenous compounds (blue dots) and spiked compounds of interest (red triangles). (a) and (c): Reversed‑phase LC 
conditions with BEH C18 stationary phase and mobile phase at pH 3; (b) and (d): HILIC conditions with bare silica stationary 
phase and mobile phase at pH 6. (a) and (b): precipitated plasma with acetonitrile (3:1, v/v); (c) and (d): diluted urine (9:1, v/v) 
with water for reversed‑phase LC or a solution of H2O/acetonitrile 25:75 for HILIC. MS intensity is represented by different blue 
shades. Black circles highlights the phospholipid region. Compounds of interest included drugs of abuse, pharmaceutical 
compounds, and doping agents. Experimental conditions are described in (61). Adapted and reproduced with permission from 
Journal of Chromatography A, A. Periat, I. Kohler, A. Thomas, R. Nicoli, J. Boccard, J.L. Veuthey, J. Schappler, and D. Guillarme, 
Systematic evaluation of matrix effects in hydrophilic interaction chromatography versus reversed phase liquid chromatography 
coupled to mass spectrometry, doi: 10.1016/j.chroma.2015.09.035 (2015) © Elsevier.
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Table 1: Commercially available HILIC stationary phase for metabolomics. 
Brand Name Chemistry
Column 
Packing*
Pore  
Size [Å]
Particle Size 
[µm]
pH Range
Agilent Technologies
Zorbax HILIC plus Unbonded silica FPP 95 3.5 0–8
Poroshell 120 HILIC Unbonded silica SPP 120 2.7 0–8
Zorbax RRHD HILIC Plus Unbonded silica (Type B) FPP 95 1.8 1–8
Zorbax RRHD 300-HILIC Unbonded silica (Type B) FPP 300 1.8 1–8
Zorbax Rx-SIL Unbonded silica FPP 80 1.8, 5 0–8
Akzo Nobel
Kromasil HILIC-D Dihydroxy groups FPP 60 5, 10 2–12
Bonna Agela
UHP HILIC Proprietary packing materials FPP 100 1.9 2–8
Unisol Amide Neutral hydrophilic amide groups FPP 100 3, 5, 10 2–8
Venusil HILIC Acrylamide bonded silica FPP 100 5 2–8
ES Industries
Epic HILIC-FL
Fluorinated-based stationary  
phase bound to silica
FPP 120 1.8 N/K
Epic HILIC-HC
Polyhydroxylated polymer coated and 
bound to silica
FPP 120 3, 5 N/K
Epic HILIC-RP
Polyhydroxylated polymer and  
C18 bound to silica
FPP 120 3, 5 N/K
Epic HILIC-PI Aromatic amine FPP 120 3, 5 N/K
Fortis Technologies
Fortis HILIC Unbonded silica FPP 100 1.7, 3, 5 2–8
Fortis HILIC diol Diol groups FPP 100 1.7, 3, 5 2–8
GL Sciences
Inertsil HILIC
Dihydroxypropyl (diol) groups bonded 
silica
FPP 100 3, 5 2–7.5
Hichrom
HALO HILIC Unbonded silica SPP 90 2.7 2–8
HALO-PentaHILIC Pentahydroxyl groups bonded silica SPP 90 2.7 2–9
Knauer
Eurospher II HILIC Zwitterionic silica (sulphobetaine) FPP 100 3, 5 2–8.5
Bluespher II HILIC Zwitterionic silica (sulphobetaine) FPP 100 2 2–8.5
Macherey-Nagel
Nucleodur HILIC Zwitterionic silica (sulphobetaine ) FPP 110 1.8, 3, 5 2–8.5
Nucleoshell HILIC Zwitterionic silica (sulphobetaine ) SPP 90 2.7 2-8.5
Merck Millipore
ZIC-HILIC Zwitterionic silica (sulphobetaine) FPP 100, 200 3.5, 5 3–8
ZIC-cHILIC Zwitterionic silica (phosphorylcholine) FPP 100 3 2–8
ZIC-pHILIC Zwitterionic polymer (sulphobetaine) FPP - 5 2–10
Nacalai
Cosmosil HILIC Charged triazole groups FPP 120 5 2–7.5
Perkin Elmer
Brownlee HILIC Unbonded silica SPP 90 2.7 2–9
Phenomenex
Luna HILIC Cross-linked diol groups FPP 200 3, 5 1.5–8
Luna NH2 Amino groups FPP 100 3, 5, 10 1.5–11
Kinetex HILIC Cross-linked diol groups SPP 100 1.7, 2.6 2–7.5
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Brand Name Chemistry
Column 
Packing*
Pore  
Size [Å]
Particle Size 
[µm]
pH Range
PolyLC Inc.
PolyHYDROXYETHYL 
Aspartamide
Hydroxyethyl groups FPP
60, 200, 
300, 1000
3, 5 3–7
PolySULFOETHYL 
Aspartamide SCX
Sulphoethyl groups FPP 200, 300 5 2.7–7
Shiseido
PC HILIC Phosphorylcholine FPP 100 3, 5 3–7.5
Capcell Core PC Phosphorylcholine SPP 90 2.7 2–7.5
SIELC
Obelisc N
Zwitterionic phase with  
hydrophilic linkage
FPP 100 5, 10 1.5–5
SiliCycle
SiliaChrom-HILIC Urea phase FPP 100 3, 5 2–8
Supelco
Ascentis Express HILIC (Si) Unbonded silica SPP 90 2.7 2–9
Ascentis Express HILIC 
OH5
Pentahydroxy phase bonded to silica 
via proprietary linkage
SPP 90 2.7 2–9
Thermo Scientific
Acclaim HILIC-10 Silica with proprietary hydrophilic layer FPP 120 3, 5 2–8
Accucore Urea-HILIC Urea phase FPP 80 2.6 2–8
Synchronis HILIC Zwitterionic silica (sulphobetaine) FPP 100 1.7, 3, 5 2–8
Accucore 150-Amide-HILIC Amide phase FPP 150 2.6 2–8
Synchronis Silica Unbonded silica FPP 100 1.7, 3, 5 2–8
Hypersil GOLD silica Unbonded silica FPP 175 1.9, 3, 5 2–8
Accucore HILIC Unbonded silica FPP 80 2.6 2–8
Hypersil Gold HILIC Polyethyleneimine FPP 175 1.9, 3, 5 2–8
Acclaim Mixed-Mode 
HILIC-1
Silica-based proprietary alkyl diol FPP 120 5 2.5–7.5
Tosoh Bioscience
TSKgel Amide-80 Carbamoyl groups bonded to silica FPP 100 3, 5, 10 2–7.5
TSKgel NH2-100 Aminoethyl groups bonded to silica FPP 100 3 2–7.5
Waters
Acquity UPLC BEH HILIC Unbonded ethylene bridged hybrid FPP 130
1.7, 2.5, 
3.5, 5
1–9
XBridge BEH HILIC Unbonded ethylene bridged hybrid FPP 130 2.5, 3.5, 5 1–9
XBridge BEH Amide
Trifunctional amide groups bonded to 
ethylene bridged hybrid substrate
FPP 130 3.5 2–11
Atlantis HILIC Unbonded silica FPP 100 3, 5, 10 1–5
Cortecs HILIC Unbonded silica SPP 90 1.6, 2.7 1–5
Acquity UPLC BEH Amide
Trifunctional amide groups bonded to 
ethylene bridged hybrid substrate
FPP 130 1.7, 3.5 2–11
YMC Europe
YMC-Triart Diol-HILIC 1,2-dihydroxypropyl FPP 120 1.9, 3, 5 2–10
YMC-Pack SIL Unbonded silica FPP
60, 120, 
200, 300
3, 5 2–7.5
YMC-Pack PVA-Sil Polyvinyl alcohol groups FPP 120 5 2–9.5
YMC-Pack CN Cyanopropy groups FPP 120, 300 3, 5 2–7.5
YMC-Pack NH2 Aminopropylsilane FPP 120 3, 5 2–7.5
* FPP, fully porous particles; SPP, superficially porous particles, N/K not known.
retention mechanism, it is difficult to evaluate the optimal 
column chemistry based on theoretical assumptions; moreover, 
the common approaches for reversed-phase LC method 
development cannot be implemented for HILIC (19,24,35). 
Hence, HILIC method development, including column selection, 
is a largely empirical process. Table 1 lists the commercially 
available HILIC stationary phases (as of November 2015), 
including the available particle sizes and working pH range. 
Commonly used chemistries in metabolomics studies include 
bare silica, diol, and amide, as well as ionic phases such 
as sulphoalkylbetaine (zwitterionic) and amine, which are of 
interest in the separation of ionized compounds via additional 
electrostatic interactions (36). As an example, Figure 1 shows 
the extracted ion chromatograms (EICs) obtained for the 
analysis of a set of representative metabolites belonging to 
different metabolic classes. The differences observed in 
chromatographic separation depending on the experimental 
conditions highlight the relative importance of stationary and 
mobile phases composition. A diol phase (Figure 1[a] and [b]) 
leads to an acceptable selectivity for the metabolites, which are 
sufficiently retained while still eluted with a moderate (< 50%) 
proportion of acetonitrile, leading to shorter analysis times when 
compared with an amine phase (Figure 1[e]) where acidic 
compounds are strongly retained as a result of electrostatic 
interactions. Retention on the cross-linked diol phase has 
been shown to mostly rely on adsorption and partitioning 
mechanisms, depending on the proportion of water in the 
mobile phase (37). Diol phases may lead to poor peak shapes 
for some compounds with peak tailing or shouldering; hence 
if peak shape is critical, for example in targeted quantitative 
metabolomics, the amine phase is an interesting alternative. 
Amine phases also show an increased peak capacity, 
particularly for small organic acids, as demonstrated in a 
systematic study by Bajad et al. (38). Zwitterionic stationary 
phases (for example, sulphoalkylbetaine, Figure 1[c] and [d]) 
are also of interest in metabolomics studies because of a large 
proportion of ionizable compounds in biofluids. However, similar 
to amine phases, zwitterionic phases present longer analysis 
times as a result of strong retention of ionized compounds. 
Differences between three HILIC materials, namely diol, 
amine, and cyano, have been compared in the context of 
urinary metabolic profiling by Kloos et al. for a large set of 
common urinary metabolites including amino acids, small 
carboxylic acids, carbohydrates, and nucleosides using 
different mobile phase compositions in both positive and 
negative ESI-MS mode (39). As shown in Figure 2(a), the 
combination of a diol column with ammonium acetate buffer 
at pH 7.0 and negative ESI mode led to the highest score in 
terms of sensitivity, peak sharpness, peak symmetry, and 
compound retention. Whatever the mobile phase conditions, 
HILIC also provided significantly better overall results than 
reversed-phase LC (core–shell C18, C18 with di-isobutyl side 
chains, and pentafluorophenyl [PFP]) for the investigated 
compounds (Figure 2[b]); these findings are in-line with other 
comparative studies (40,41). Therefore, a diol phase combined 
with ammonium acetate buffer at a pH of approximately 6–7 
appears to give the optimal separation conditions in the context 
of untargeted metabolomics. In the case of unsatisfactory 
results, experimental parameters (stationary phase, as well as 
mobile phase composition, ionic strength, and pH) have to be 
tested to select the adequate conditions adapted to the purpose 
of the study. In addition to the documentation provided by 
manufacturers, useful guidelines and comprehensive studies 
are available to help in method development and selection of 
optimal experimental conditions for non-experienced users 
(38,39,42–45). 
As a result of its complexity, HILIC is well known for a higher 
retention time variability compared to reversed-phase LC, 
mainly explained by inter-day drifts in pH or ionic strength of 
the buffer used (46,47). On the other hand, the effect of the 
column temperature seems to have a rather limited effect on 
the retention of hydrophilic compounds (18,19,46). During the 
preparation of the aqueous buffer it is therefore crucial to ensure 
repeatable procedures. Both buffer concentration and pH should 
be carefully selected according to the compounds of interest 
and the stationary phase, ensuring a sufficient buffer capacity 
and, thus, repeatable results. Modifying the buffer concentration 
(commonly ≤50 mM as a result of limited salt solubility in 
acetonitrile) has a significant impact on electrostatic interactions, 
where an increase in ionic strength usually leads to disruption 
of ionic interactions and, thus, lower retention of ionized 
compounds (18). Moreover, the salt concentration modifies the 
thickness of the water layer, which also influences the hydrophilic 
partitioning and retention of uncharged compounds (18,19). 
As a result of their MS compatibility, the vast majority of HILIC 
separations in metabolomics have been performed using 
formate and acetate-based buffers. Ammonium-based salt 
buffers give better results than the corresponding acid solutions. 
Indeed, peak shapes for ionogenic solutes, especially basic 
compounds, are considerably worse when using formic acid in 
the buffer instead of ammonium formate (48). This peak distortion 
has been observed for bare silica, amide, zwitterionic, and silica 
hybrid phases. The presence of salt buffers improves the peak 
shape via increased ionic strength of the mobile phase and 
positively impacts the formation of the water layer on the column 
surface (48,49). 
An adequate and repeatable buffer pH is crucial in HILIC 
since the separation mechanisms partly rely on the pKa of 
analyte and stationary phase. However, the effect of the buffer 
pH is difficult to predict since pH and pKa are strongly affected 
by the presence of organic solvents. Highly organic mobile 
phases are therefore expected to present different apparent pH 
values, which may vary significantly during the gradient (49–51). 
Different mobile phase pH should therefore be practically 
tested, especially with ionizable stationary phases. 
Acetonitrile remains the optimal organic solvent for HILIC 
analysis because it is water-miscible and aprotic. Protic 
solvents such as methanol, iPA, and EtOH, as well as cyclic 
ethers such as tetrahydrofuran are not recommended because 
of competition with water for the solvation of the stationary 
phase, which may lead to lower retention (19). During times of 
acetonitrile shortage, acetone can be used instead, but its use 
is rather limited in combination with UV (UV absorbance of the 
ketone function) or MS detection (formation of condensation 
products) (52). In HILIC, a typical gradient should start with 
at least 3–5% of water to ensure a repeatable formation of the 
water-rich layer and should not go beyond 35–40% to avoid 
water saturation and, thus, disruption of the aqueous layer. 
However, in many metabolomics applications, this proportion 
of water is not sufficient to elute all the polar compounds, 
especially when working with ionized surfaces such as 
sulphoalkylbetaine and amine (Figure 1). An extended gradient 
with a higher proportion of buffer, up to 90–95%, is often 
needed to break the electrostatic interactions and allow for 
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compound elution. In this context, the water layer is disrupted 
and partitioning mechanisms are reduced. The re-equilibration 
time should therefore be sufficiently long (corresponding to at 
least 10–20 column volumes) to restore the water-rich layer prior 
to the next injection.
The latest developments in column manufacturing have been 
mostly focused on sub-2-µm and sub-3-µm superficially porous 
particles to allow for a better separation efficiency and peak 
capacity, similar to reversed-phase LC (17). Most HILIC phases 
(bare silica, amine, amide, diol, zwitterionic, and cyano; see 
Table 1) also exist in UHPLC column formats, while some new 
phase chemistries are also available, including HILIC phases 
that include aromatic amines and fluorinated groups. 
Columns equipped with superficially porous particles 
(SPPs) are also commercially available but limited to some 
phases (bare-silica and diol for sub-2-µm core–shell as well 
as bare-silica, diol, and zwitterionic for sub-3-µm core–shell 
particles, respectively). The kinetic performance of a sub-2-µm 
core–shell bare-silica column is significantly improved 
compared with fully porous columns, which can possibly be 
attributed to a superior bed homogeneity and improved thermal 
conductivity (53). As a result of the lower viscosity of acetonitrile, 
a lower back pressure (two- to threefold) is observed in HILIC 
compared to reversed-phase LC if a conventional gradient 
is applied. Combining HILIC with UHPLC technology and 
superficially porous particles also enables the use of higher flow 
rates, allowing for high-throughput analysis, which is beneficial 
to metabolomics studies. HILIC–UHPLC–MS has already 
shown its potential in some metabolomics studies (54–57) but 
remains rarely used with superficially porous particles (58). 
Extending the commercially available stationary phase diversity 
with sub-2-µm and sub-3-µm superficially porous particles will 
certainly foster the rise of HILIC in metabolomics. 
Mass Spectrometric Detection
HILIC has demonstrated an increased ESI-MS sensitivity 
compared to reversed-phase LC as a result of the high proportion 
of organic modifier in the eluent. Most notably, acetonitrile shows 
a lower dielectric constant than aqueous buffers, leading to 
better droplet formation and enhanced desolvation efficiency 
(59). The improvement in sensitivity depends on the proportion 
of acetonitrile in the mobile phase, flow rate, and ESI source 
geometry, as well as retention of the compounds of interest. For 
instance, a fourfold median enhancement of sensitivity has been 
observed on a set of basic compounds covering a broad range 
of physico-chemical properties (22). Even if more than 80% of 
the tested compounds showed a better sensitivity in HILIC–MS, 
large differences were observed within the studied compound 
set where some analytes demonstrated an improvement factor of 
>100-fold; however, such improvements are also dependent on 
the mass analyzer used. 
Matrix effects represent a serious challenge in metabolomics. 
Keeping the sample pre-treatment as simple as possible 
significantly increases the risk of MS signal suppression or 
enhancement because of co-elution of interferents with the 
analytes of interest. In the context of plasma analysis, HILIC 
has demonstrated that it is globally more prone to matrix 
effects than reversed-phase LC as a result of the co-elution of 
matrix components such as urea, creatinine, sphingomyelins, 
phospholipids, salts, and choline – components that are poorly 
(or strongly for lipids) retained in reversed-phase LC (60). 
Using a 2D-representation, Figure 3 illustrates the differences 
observed in chromatograms obtained in reversed-phase 
LC (BEH C18) and HILIC (bare silica) with an injection of 
precipitated plasma (Figure 3[a] and [b]) and diluted urine 
(Figure 3[c] and [d]) (61). In diluted urine, matrix effects are 
expected to be less prone using HILIC because of the elution 
of matrix components over the whole gradient compared to 
reversed-phase LC where interferents are clustered in certain 
regions of the chromatogram. Therefore, it remains difficult 
to draw a clear relationship between the chromatographic 
conditions and the prevalence of matrix effects (12,61). Hence, 
it is very important in metabolomics studies that matrix effects 
are qualitatively investigated and quantitatively assessed during 
method development on a representative set of metabolites, 
for instance using post-column infusion experiments (62) or 
post-extraction addition methods (63,64). The use of stable 
isotopically labelled internal standards is also strongly advised 
to ensure accurate measurements (65). 
Data Analysis 
As a result of the lower retention time repeatability and broader 
peaks obtained compared to reversed phase-LC, the data 
pre-processing step (including peak picking, alignment, 
scaling, and normalization) is of high importance in HILIC 
analysis to obtain a reliable matrix containing the metabolic 
features detected. Adequate peak picking relies on aligned 
chromatograms; indeed, a high variability in retention times 
increases the risk of wrongly assigning two chromatographic 
peaks to two different features in the peak-matching step. 
Therefore, alignment of the data is crucial and can be 
performed by open-source software or algorithms. For instance, 
algorithms developed for CE–MS data (which presents relatively 
high migration time variability) such as msalign2 (66) also 
provide appropriate results for HILIC data.
Subsequently, peak picking can be performed with open 
access (for example, centWave algorithms available in the 
XCMS package from the Scripps Institute) or commercial 
algorithms commonly used in reversed-phase LC–MS, bearing 
in mind both the larger peak widths and the multiple adducts 
expected (for example, acetate adducts for lipids) that are 
inherent to the mobile phase composition. To correct for the 
possible overestimation of the total number of metabolites 
because of multiple adduct formation, adduct-finding scripts 
can be used. Finally, the remaining pre-processing steps 
such as scaling and normalization as well as multivariate 
data analysis do not significantly differ from reversed-phase 
LC-based metabolomics approaches (67–69). 
Compound identification is a critical step to convert the 
observed differences between populations into biological 
information and is known to be very challenging in 
reversed-phase LC-based metabolomics. A metabolite is 
considered identified if a minimum of two independent and 
orthogonal data (such as retention time and mass spectrum) 
has been acquired and directly compared to an authentic 
reference standard analyzed under identical experimental 
conditions (68,70). HILIC data therefore shows an additional 
level of difficulty because of the multiple adducts observed, 
which complicates the search in common databases (such as 
HMDB, METLIN, and KEGG). Moreover, the relatively lower 
column batch-to-batch repeatability represents an additional 
challenge because injection of authentic reference standards 
generally occurs at a later stage of the process, generally on a 
different column than the one used for sample analysis.
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Applications in Untargeted Clinical Metabolomics
Few studies using HILIC in untargeted clinical metabolomics 
have been published so far, often in combination with 
reversed-phase LC to obtain the broadest possible metabolic 
coverage (43,71–73). Idborg et al. proposed the first metabolic 
fingerprinting using HILIC–MS 10 years ago on rat urine (74). 
In this study, urine samples were first treated by solid-phase 
extraction (SPE) (hydrophilic–lipophilic-based sorbent) where 
the wash fraction was analyzed using HILIC–MS (ZIC-HILIC 
stationary phase) and the eluate by reversed-phase  
LC–MS, respectively. By comparing the metabolic fingerprints 
measured in both chromatographic modes, the authors showed 
the complementary nature of HILIC for the confirmation of 
reversed-phase LC results and its ability to detect unique 
variables (75). These early results were confirmed by Gika et al. 
who combined HILIC and UHPLC technology for the first time 
using a bare silica column packed with sub-2-µm particles for 
the analysis of obese and lean Zucker rats (76). More features 
(approximately 30%) were tracked with reversed-phase  
LC–UHPLC than HILIC–UPHLC; this was likely a result of the 
sub-optimal HILIC experimental conditions. Nevertheless, 
based on principal component analysis, the latter allowed 
for the detection of important polar metabolites that were 
not highlighted in reversed-phase LC, demonstrating the 
importance of both techniques for an improved metabolic 
coverage. 
Subsequent comparative studies clearly demonstrated the 
complementary nature of reversed-phase LC and HILIC in 
multiple and diverse applications including toxicological studies 
(77), renal carcinoma (78), lung cancer (79), oral squamous 
cell carcinoma (80), or heart failure (81), emphasizing that both 
techniques would bring orthogonal information and should 
therefore be considered together in untargeted metabolomics. 
Siuzdak and co-workers compared both techniques for the 
metabolic profiling of different samples including E. coli cells, 
cancer cells, and human plasma (82). For instance, they 
showed that an aminopropyl-based HILIC–MS method with 
negative ESI mode underlined key dysregulated metabolites 
in central carbon pathways, while reversed-phase LC–MS in 
positive ESI mode detected unique features belonging to lipid 
metabolism pathways. The two chromatographic modes were 
integrated into a single extraction-dual separation workflow 
where samples were first mixed with an 80% organic solvent 
mixture (methanol:acetonitrile:water 2:2:1, v/v/v) for PP prior 
to reconstitution in acetonitrile:water 1:1 (v/v) that allowed for 
dissolution of both polar and nonpolar metabolites, as well as 
injection on both platforms. 
The future of untargeted metabolomics will likely bring 
more comprehensive studies systematically combining 
reversed-phase LC and HILIC. In this context, the on-line 
combination of both techniques represents an excellent 
possibility to offer a complete automation of the acquisition 
process and allow for high-throughput analysis, which is highly 
beneficial in large cohort metabolomics studies (83,84). 
Conclusions
HILIC offers numerous advantages for the analysis of relatively 
polar compounds including better retention, orthogonal 
selectivity compared to reversed-phase LC, and improved 
sensitivity. Nevertheless, HILIC remains underestimated 
and little used in metabolomics as a result of lower retention 
time repeatability and poorer peak shape. These limitations, 
inherent to the multimodal mechanisms involved in HILIC 
retention, have increased the reluctance of non-experienced 
users for this technique. Even if HILIC is not as straightforward 
as reversed-phase LC, high-quality metabolomics data are 
ensured if good practice is followed during the entire analytical 
process, including (i) a careful selection of the sample diluent 
and volume of injection; (ii) use of ammonium-based salt buffers 
at a fixed and reproducible pH value and ionic strength; (iii) 
adaptation of the gradient profile to the stationary phase and 
compounds of interest; (iv) evaluation of matrix effects; and (v) 
careful selection of the data pre-processing parameters. 
The selection of the best stationary phase in metabolomics 
studies also appears challenging since there is currently 
no equivalent to the versatile C18 used in the majority of 
reversed-phase LC applications. Diol phases combined with a 
mobile phase containing a volatile buffer at a relatively neutral 
pH value offer the highest performance in terms of selectivity, 
sensitivity, and peak shape and can thus be considered as a 
good starting point in metabolomics studies prior to fine tuning 
of the experimental conditions. The development of novel and 
reproducible commercially available HILIC columns, equipped 
with sub-2-µm fully porous or sub-3-µm superficially porous 
particles, will certainly encourage a more widespread use 
of HILIC in metabolomics as a complementary technique to 
reversed-phase LC to obtain the highest possible metabolic 
coverage.
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